335-OR: Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Dual Agonist, Was Safe and Well Tolerated and Showed Dose-Dependent Body Weight Loss over Four Weeks in Healthy Subjects
Year: 2022
Type: article
Source: Diabetes
DOI: 10.2337/db22-335-or
Authors: MINNA B. OLSEN, ULRIKE HÖVELMANN, JON GRIFFIN, KIM M. KNUDSEN, PER-OLOF ERIKSSON, MIKKEL A. AGERSNAP
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281752313
